REG - Sareum Holdings PLC - Notice of AGM, Annual Report and Accounts

Sareum HoldingsAnnouncement

17/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251117:nRSQ7623Ha&default-theme=true

RNS Number : 7623H  Sareum Holdings PLC  17 November 2025

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of AGM, Annual Report and Accounts

Cambridge, UK, 17 November 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, today announces that the
Company's Annual General Meeting ("AGM") will be held at 10.00am GMT on
Tuesday 9 December 2025 at the offices of ICR Healthcare, 85 Gresham Street,
London EC2V 7NQ.

 

In order to allow shareholders to follow the proceedings of the AGM without
attending in person, the Company will provide access online via the Investor
Meet Company ("IMC") platform. Shareholders who wish to attend the AGM
remotely should register for the event in advance by using the following
link: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
(https://url.us.m.mimecastprotect.com/s/NAZuCn5YgvCA2OBXt9fACJxF1a?domain=investormeetcompany.com)
. Investors who already follow Sareum Holdings plc on the IMC platform will
automatically be invited.

 

Shareholders are invited to submit questions for the Board to consider in the
Q&A session to be held immediately after the AGM. Questions can be pre
submitted via the IMC Platform up until 8 December 2025, 9.00am GMT and can be
submitted at any time during the AGM itself. Shareholders are reminded that
they will not be able to vote online at the AGM via the IMC platform and are
therefore requested to submit their votes via proxy, as early as possible.

 

Shareholders intending to vote should submit their vote online via the
Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/
(https://uk.investorcentre.mpms.mufg.com/) where details of the procedure are
shown. If you have not done so already, you will need to register your account
using your Investor Code, which can be found on your share certificate. If you
hold your shares in CREST and wish to vote via the Investor Centre rather than
the CREST electronic proxy appointment services please contact our registrars,
MUFG Corporate Markets to obtain your Investor Code (via email at
shareholderenquiries@cm.mpms.mufg.com or call the registrars' helpline on 0371
664 0300, calls are charged at the standard geographic rate and will vary by
provider;  if you are outside the United Kingdom, please call +44 371 664
0300, calls will be charged at the applicable international rate).
Alternatively, you may request a paper form of proxy from our registrars.

 

The notice of AGM, along with a copy of the Company's annual report and
accounts for the year ended 30 June 2025, will be posted shortly to those
shareholders who requested a hard copy. A copy of both documents will also be
available on the Company's website: www.sareum.com (http://www.sareum.com/)
in the Investor Relations section.

 

For further information:

 

 Sareum Holdings plc

 Stephen Parker, Executive Chairman                  01223 497700

                                                     ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Singer Capital Markets (Joint Corporate Broker)     020 7496 3000

 Phil Davies, Patrick Weaver

 Oberon Capital (Joint Corporate Broker)             020 3179 5300

 Mike Seabrook / Nick Lovering

 ICR Healthcare (Financial PR)                       020 3709 5700

 Jessica Hodgson / Davide Salvi

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy, and has recently initiated a preclinical
programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such
as multiple sclerosis and Parkinson's disease.

The Company is the license holder for SRA737, a clinical-stage Checkpoint
kinase 1 inhibitor that targets cancer cell replication and DNA damage repair
mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUNAKRVUUAAAA



            Copyright 2019 Regulatory News Service, all rights reserved